Disclaimer: I am not a financial advisor, you should never take my advice. These are my notes, my personal understanding as a part of daily / weekly stock investment researching. Feel free to get feel of what may be important or notable, but I am not making any recommendation here...
Morning MoneyBeat: Nasdaq Approaches Dot-Com Era Record (source: Wall Street Journal #MoneyBeat)Now the tech-heavy index sits less than 3% from its record destination and few on Wall Street expect it to stall before it gets there. That’s because after outperforming the broader indexes in 2014, tech is leading the overall market again this year. And Wall Street largely forecasts the sector to lead for the rest of 2015.
The video above: Gilead Tractor Supply Keurig and Monster Beverages Has Been Leading the Record Nasdaq Surge. Nasdaq is hoping to break record. 4000%+ gainAmong Nasdaq 100 Best Formers: Gilead 4509%+, Tractor Supply Co 7489%+, Keurig 29547%, monster 44448% (if existed in March 2000, otherwise adjusted to model as if existed). Since 2009 best performers include Regeneron Pharma Sirius XM Keurig Green Mountain, Starbucks, Netflix, Priceline, Baidu,
The above video also briefly mentioned Apple as a leader.
Mark Zuckerberg says Happy New Year in Mandarin (Source: CNN Money)For unclear reasons why it is relevant, Facebook founder Mark Zuckerberg wishes everyone a Happy Chinese New Year 2015 in awesome Mandarin Chinese language. Does this signifiy a new era of Facebook expansion into China... finally?
Analysts Respond to Pharmacyclics' Q4 Results - S&P Capital IQ
Pharmacyclics, Inc.(NASDAQ: PCYC) reported Q4 results on Wednesday and posted adjusted of EPS $0.96, above estimates of $0.76, on revenues of $290.2 million. The company also reaffirmed its fiscal 2015 outlook. JP Morgan analyst Cory Kasimov felt that the company's long-term future looked bright, however, the stock's valuation prompted the firm to "step to the sidelines." Kasimov downgraded the stock from Overweight to Neutral (the price is getting too high JPM starts to think it's overpriced). Nomura analyst M. Ian Somaiya, to a different view, upgraded the stock from Neutral to Buy. Somaiya added that "upside to consensus US revenue estimates combined with a strong launch in Europe and multiple clinical data readouts that could guide label expansion opportunities in the future support our upgrade." Stifel analyst Brian Klein stated that with "Zydelig's 4Q14 print of $16M in the U.S., we see the greater than 10-times comparative Imbruvica sales margin supporting our belief that Imbruvica is the established SOC for R/R CLL." Klein maintained a Hold rating on the stock and believed "that 2015 could be a transformational year for PCYC as it seeks to shift from the limited relapsed and refractory CLL market to the larger heme-onc space, including front-line CLL and NHL." Pharmacyclics recently traded at $170.51, up 0.18 percent. View More Analyst Ratings for PCYCView the Latest Analyst Ratings 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Acquire Media
Post a Comment